vs
MetroCity Bankshares, Inc.（MCBS）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
MetroCity Bankshares, Inc.的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.2倍（$43.7M vs $35.5M），MetroCity Bankshares, Inc.净利率更高（50.5% vs -304.2%，领先354.7%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 23.6%），MetroCity Bankshares, Inc.自由现金流更多（$37.0M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 15.7%）
MetroCity Bankshares, Inc.旗下的大都会城市银行是一家韩裔美国人创办的银行，总部位于佐治亚州多拉维尔，提供个人及商业银行服务。它是总部不在加利福尼亚州洛杉矶的最大韩美系银行，目前在德克萨斯、纽约、新泽西、弗吉尼亚、佐治亚、阿拉巴马和佛罗里达共设有19家分行。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
MCBS vs RXRX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $43.7M | $35.5M |
| 净利润 | $18.1M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 52.8% | -304.8% |
| 净利率 | 50.5% | -304.2% |
| 营收同比 | 23.6% | 681.7% |
| 净利润同比 | 11.7% | 39.6% |
| 每股收益（稀释后） | $0.69 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $43.7M | $35.5M | ||
| Q3 25 | $38.0M | $5.2M | ||
| Q2 25 | $37.9M | $19.2M | ||
| Q1 25 | $36.0M | $14.7M | ||
| Q4 24 | $35.4M | $4.5M | ||
| Q3 24 | $36.9M | $26.1M | ||
| Q2 24 | $36.3M | $14.4M | ||
| Q1 24 | $32.7M | $13.8M |
| Q4 25 | $18.1M | $-108.1M | ||
| Q3 25 | $17.3M | $-162.3M | ||
| Q2 25 | $16.8M | $-171.9M | ||
| Q1 25 | $16.3M | $-202.5M | ||
| Q4 24 | $16.2M | $-178.9M | ||
| Q3 24 | $16.7M | $-95.8M | ||
| Q2 24 | $16.9M | $-97.5M | ||
| Q1 24 | $14.6M | $-91.4M |
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
| Q4 25 | 52.8% | -304.8% | ||
| Q3 25 | 62.8% | -3327.6% | ||
| Q2 25 | 62.4% | -916.8% | ||
| Q1 25 | 61.3% | -1297.9% | ||
| Q4 24 | 58.9% | -4042.4% | ||
| Q3 24 | 61.4% | -377.1% | ||
| Q2 24 | 64.4% | -697.4% | ||
| Q1 24 | 62.6% | -698.4% |
| Q4 25 | 50.5% | -304.2% | ||
| Q3 25 | 45.5% | -3135.3% | ||
| Q2 25 | 44.4% | -894.2% | ||
| Q1 25 | 45.3% | -1373.3% | ||
| Q4 24 | 54.0% | -3935.5% | ||
| Q3 24 | 45.3% | -367.5% | ||
| Q2 24 | 46.7% | -676.6% | ||
| Q1 24 | 44.8% | -662.4% |
| Q4 25 | $0.69 | $-0.17 | ||
| Q3 25 | $0.67 | $-0.36 | ||
| Q2 25 | $0.65 | $-0.41 | ||
| Q1 25 | $0.63 | $-0.50 | ||
| Q4 24 | $0.64 | $-0.56 | ||
| Q3 24 | $0.65 | $-0.34 | ||
| Q2 24 | $0.66 | $-0.40 | ||
| Q1 24 | $0.57 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $383.7M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $544.2M | $1.1B |
| 总资产 | $4.8B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
| Q4 25 | $383.7M | $743.3M | ||
| Q3 25 | $227.2M | $659.8M | ||
| Q2 25 | $286.0M | $525.1M | ||
| Q1 25 | $285.1M | $500.5M | ||
| Q4 24 | $249.9M | $594.4M | ||
| Q3 24 | $291.2M | $427.6M | ||
| Q2 24 | $327.9M | $474.3M | ||
| Q1 24 | $258.8M | $296.3M |
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
| Q4 25 | $544.2M | $1.1B | ||
| Q3 25 | $445.9M | $1.0B | ||
| Q2 25 | $436.1M | $919.1M | ||
| Q1 25 | $428.0M | $933.9M | ||
| Q4 24 | $421.4M | $1.0B | ||
| Q3 24 | $407.2M | $524.6M | ||
| Q2 24 | $407.2M | $584.4M | ||
| Q1 24 | $396.6M | $401.2M |
| Q4 25 | $4.8B | $1.5B | ||
| Q3 25 | $3.6B | $1.4B | ||
| Q2 25 | $3.6B | $1.3B | ||
| Q1 25 | $3.7B | $1.3B | ||
| Q4 24 | $3.6B | $1.4B | ||
| Q3 24 | $3.6B | $726.5M | ||
| Q2 24 | $3.6B | $775.9M | ||
| Q1 24 | $3.6B | $557.8M |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $37.7M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $37.0M | $-47.3M |
| 自由现金流率自由现金流/营收 | 84.7% | -133.1% |
| 资本支出强度资本支出/营收 | 1.5% | 3.5% |
| 现金转化率经营现金流/净利润 | 2.08× | — |
| 过去12个月自由现金流最近4个季度 | $79.4M | $-378.3M |
8季度趋势，按日历期对齐
| Q4 25 | $37.7M | $-46.1M | ||
| Q3 25 | $16.5M | $-117.4M | ||
| Q2 25 | $14.5M | $-76.4M | ||
| Q1 25 | $11.9M | $-132.0M | ||
| Q4 24 | $63.5M | $-115.4M | ||
| Q3 24 | $-11.5M | $-59.2M | ||
| Q2 24 | $19.4M | $-82.2M | ||
| Q1 24 | $36.4M | $-102.3M |
| Q4 25 | $37.0M | $-47.3M | ||
| Q3 25 | $16.2M | $-117.6M | ||
| Q2 25 | $14.3M | $-79.6M | ||
| Q1 25 | $11.8M | $-133.8M | ||
| Q4 24 | $62.2M | $-116.7M | ||
| Q3 24 | $-11.8M | $-63.8M | ||
| Q2 24 | $19.0M | $-83.4M | ||
| Q1 24 | $36.1M | $-109.0M |
| Q4 25 | 84.7% | -133.1% | ||
| Q3 25 | 42.7% | -2272.5% | ||
| Q2 25 | 37.8% | -413.9% | ||
| Q1 25 | 32.9% | -907.4% | ||
| Q4 24 | 175.8% | -2567.7% | ||
| Q3 24 | -31.9% | -244.6% | ||
| Q2 24 | 52.4% | -578.5% | ||
| Q1 24 | 110.6% | -789.9% |
| Q4 25 | 1.5% | 3.5% | ||
| Q3 25 | 0.7% | 4.7% | ||
| Q2 25 | 0.3% | 16.4% | ||
| Q1 25 | 0.2% | 12.4% | ||
| Q4 24 | 3.6% | 28.6% | ||
| Q3 24 | 0.8% | 17.5% | ||
| Q2 24 | 1.0% | 8.2% | ||
| Q1 24 | 0.7% | 48.2% |
| Q4 25 | 2.08× | — | ||
| Q3 25 | 0.95× | — | ||
| Q2 25 | 0.86× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 3.91× | — | ||
| Q3 24 | -0.69× | — | ||
| Q2 24 | 1.14× | — | ||
| Q1 24 | 2.49× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
